Terminated PHASE1 INTERVENTIONAL 1-arm NCT06695507

Upfront Ruxolitinib for Chronic Graft-vs-host Disease

Upfront Ruxolitinib Treatment for Chronic Graft-vs-host Disease in Children and Young Adults: A Corticosteroid-sparing Pilot Study

Sponsor: Children's Hospital Medical Center, Cincinnati

Conditions Chronic Graft Versus Host Disease

Interventions Ruxolitinib

Updated 4 times since 2024 Last updated: Feb 23, 2026 Started: Feb 19, 2025 Primary completion: Aug 20, 2025 Completion: Sep 18, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study closed due to slow enrollment.

Other terminated trials from Children's Hospital Medical Center, Cincinnati

See all terminations from Children's Hospital Medical Center, Cincinnati

Other Chronic Graft Versus Host Disease trials with similar outcome

Browse all Chronic Graft Versus Host Disease trials

Listed as NCT06695507, this PHASE1 trial focuses on Chronic Graft Versus Host Disease and remains terminated or withdrawn. Sponsored by Children's Hospital Medical Center, Cincinnati, it has been updated 4 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Terminated PHASE1

Status: Recruiting → Terminated
Jun 2025 — Feb 2026 [monthly]

Recruiting PHASE1
Mar 2025 — Jun 2025 [monthly]

Recruiting PHASE1
Dec 2024 — Mar 2025 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Hospital Medical Center, Cincinnati

Data source: Children's Hospital Medical Center, Cincinnati

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States